CAMBRIDGE, MA--(Marketwired - October 10, 2013) - Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, will host a webcast and conference call for the Duchenne muscular dystrophy (DMD) community on Thursday, October 17, 2013, beginning at 12:00 p.m., Eastern Time (9:00 a.m., Pacific Time). Chris Garabedian, president and chief executive officer, and Edward Kaye, M.D., chief medical officer, will provide information and answer questions about Sarepta's DMD development program, including current and planned clinical trials, and Let's Skip Ahead, a new online resource center from Sarepta for patients and families available at www.skipahead.com.
Sarepta has invited DMD community representatives from leading patient advocacy groups including Cure Duchenne, Duchenne Alliance, Muscular Dystrophy Association and Parent Project Muscular Dystrophy to participate in the question and answer portion of the webcast. Patients and families who have questions about Sarepta's DMD development program are encouraged to share them with any one of these groups prior to the event.
To access the webcast, visit the events and presentations section of Sarepta's website at www.sarepta.com/events and follow the link for the webcast under "Upcoming Events." Please connect several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
To access only the audio portion, dial in to 1-888-895-5479 (toll free) or 1-847-619-6250. The passcode for the call is 35883585. Please specify to the operator that you would like to join the "Sarepta DMD Development Program Update."
Following the event, the webcast will be archived in the events and presentations section of Sarepta's website for 90 days.
About Sarepta Therapeutics
Sarepta Therapeutics is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world's most lethal infectious diseases. Sarepta aims to build a leading, independent biotech company dedicated to translating its RNA-based science into transformational therapeutics for patients who face significant unmet medical needs. For more information, please visit us at www.sarepta.com.